Drug Profile
KUR 111
Alternative Names: I-0401Latest Information Update: 31 Jul 2019
Price :
$50
*
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences
- Class Blood proteins; Peptides
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Fracture
Most Recent Events
- 31 Jul 2019 KUR 111 is still in phase II trials for Fracture in Germany, Hungary, Italy, Poland, Spain, Switzerland and United Kingdom (Intralesional)
- 30 Jun 2016 KUR 111 is available for licensing as of 28 Jun 2016. http://www.kuros.ch/
- 09 Oct 2015 Efficacy and adverse events data from a phase IIb trial in Fractures released by Kuros